PlainPill

Semaglutide

Also known as Ozempic, Wegovy, Rybelsus

The short answer. More people than not who report on Semaglutide say it helped (64% of 228). It is most often used for weight loss: 85% of 138 reports say that improved. It is well studied — 421 meta-analyses on PubMed. The most common complaint is nausea.

What users report
64%helped228 reports · high confidence
145 helped59 mixed23 didn't help

From 330 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
421
meta-analyses
307
RCTs
5,603
papers
Prescription medication. These are self-reported experiences, not dosing or treatment advice. Prescription drugs have real side effects and interactions — start, stop or change them only with a doctor. Share of positive reports is not a measure of safety.

What Semaglutide does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 421 meta-analyses on PubMed ↗ · 307 randomized trials ↗

J ASEAN Fed Endocr Soc · 2022 · Meta-analysis / systematic review
Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis

Conclusion: Among individuals with obesity without type 2 diabetes, subcutaneous semaglutide is effective for weight loss with an 11.85% reduction from baseline compared to placebo. This supports the use of semaglutide for weight management in obesity. However, risk of gastrointestinal adverse events, discontinuation of treatment and serious adverse events were higher in the semaglutide group versus placebo.

PubMed 36578889 ↗
Obes Rev · 2025 · Meta-analysis / systematic review
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis

Conclusion: The proportion of weight regained was proportional to the amount originally lost. Meaning: Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity.

PubMed 40186344 ↗
Registered clinical trials

778 human trials on ClinicalTrials.gov test Semaglutide — 350 completed, 167 recruiting now. See all on ClinicalTrials.gov ↗

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

FDA drug label

Boxed warning (the FDA's strongest label warning): “RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether OZEMPIC causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human…”

Full label on DailyMed (NIH) ↗

FDA recalls

48 recalls of products named for Semaglutide. Most recent:

  • 2026-08-19 · Class II: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material record ↗
  • 2026-04-22 · Class II: Lack of Assurance of Sterility record ↗
  • 2026-03-11 · Class II: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution record ↗

Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗

Liver safety (LiverTox, NIH)

LiverTox rates Semaglutide D — a possible rare cause of liver injury (1–3 published cases). LiverTox entry ↗

US government research funding (NIH)

NIH has funded 21 research projects with Semaglutide in the title, $18,663,689 in total (2021–2026). NIH RePORTER ↗

Plain-language guides from the US government: MedlinePlus: Semaglutide ↗

Dosage people report

We don't list doses for prescription medications. Dosing should only come from a doctor or pharmacist.

Reported side effects

How often each side effect came up across all reports.

nausea ×35fatigue ×20stomach issues ×11constipation ×9vomiting ×6anhedonia ×5headache ×5depression ×3

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
HelpedRead the discussion ↗
“I tried ozempic at first. Made me really sick so I stopped.”
Didn't helpRead the discussion ↗
“Other things I take are semiglutide and TRT... recently made some major life changes and lost 80 pounds.”
HelpedRead the discussion ↗
“I recently cycled off Ozempic after 6 months. It did not agree with me...profund depression...profound depression(something I dont normally have an issue with).”
MixedRead the discussion ↗
Read more Semaglutide reviews →
Top discussions (5)

Semaglutide compared

Other options for weight loss

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate